Development of Inhibitors of the Aspartyl Protease Renin for the Treatment of Hypertension

Publisher： Bentham Science Publishers

E-ISSN： 1875-5550|7|3|241-254

ISSN： 1389-2037

Source： Current Protein and Peptide Science, Vol.7, Iss.3, 2006-06, pp. : 241-254

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Engineered Protein Protease Inhibitors

By  

Current Enzyme Inhibition, Vol. 5, Iss. 2, 2009-07 ,pp. : 87-98

Bentham Science Publishers

Access to resources Recommend Favorite

Protease Inhibitors with Antileishmanial Activity

By  

Current Enzyme Inhibition, Vol. 7, Iss. 1, 2011-02 ,pp. : 24-31

Bentham Science Publishers

Access to resources Recommend Favorite

Development of Hedgehog Pathway Inhibitors (HPI) in Treatment of Cancer

By  

Current Chemical Biology, Vol. 8, Iss. 3, 2014-12 ,pp. : 132-148

Bentham Science Publishers

Access to resources Recommend Favorite

Chronic etanercept treatment prevents the development of hypertension in fructose-fed rats

By Tran Linda   MacLeod Kathleen   McNeill John  

Molecular and Cellular Biochemistry, Vol. 330, Iss. 1-2, 2009-10 ,pp. : 219-228

Springer Publishing Company

Access to resources Recommend Favorite

Macrocyclic inhibitors for the serine protease plasmin

By Xue Fengtian   Seto Christopher T.  

Journal of Enzyme Inhibition and Medicinal Chemistry, Vol. 24, Iss. 3, 2009-06 ,pp. : 779-794

Informa Healthcare

Access to resources Recommend Favorite